Key Takeaways
- • Ansa Biotechnologies, a DNA synthesis provider based in Emeryville, California, closed a $71.5 million oversubscribed Series C financing led by Blue Water Life Science Advisors.
- • The round lifts Ansa's total funding to $211 million, according to the company's announcement.
- • New investors include Illumina Ventures, BEVC, Lightscape Partners, and Agent Capital, joining existing backers Cerberus Ventures, Fall Line Capital, Dauntless Ventures, and Altitude Life Science Ventures.
- • The raise is driven by accelerating demand for Ansa's ability to deliver long, complex synthetic DNA with a guaranteed ship date.
Summary
The financing comes amid growing demand for Ansa's core offering: the ability to deliver long, complex synthetic DNA with a guaranteed ship date. The company states this capability allows researchers to pursue more ambitious experiments using biological designs that conventional synthesis methods struggle to manufacture.
The round included new investors Illumina Ventures, BEVC, Lightscape Partners, and Agent Capital. Existing investors Cerberus Ventures, Fall Line Capital, Dauntless Ventures, and Altitude Life Science Ventures also participated. The announcement did not disclose a valuation or the intended use of the new capital.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.